Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Meta Expands AI Training With Employee Activity Tracking Tools 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
KING OF PRUSSIA, Pa., March 10, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the 2017 Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 11:15 a.m. EDT in Miami.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
